Analysis of outcomes by patient subgroups in patients with myelofibrosis treated with pacritinib vs best available therapy (BAT) in the phase III persist-1 trial.
Authors
Vannucchi, AMesa, R
Cervantes, F
Prasad, R
Jakucs, J
Elinder, A
Recher, C
te Boekhorst, P
Knapper, S
Somervaille, Tim C P
Dean, J
Granston, T
Mead, A
Harrison, C
Affiliation
University of Florence, Florence, ItalyIssue Date
2015